Coronary heart disease in HIV-infected individuals

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 4, 2003, Pages 506-512

  Currier, Judith S ^a   Taylor, Anne ^b   Boyd, Felicity ^c   Dezii, Christopher M ^d   Kawabata, Hugh ^d   Burtcel, Beth ^d   Maa, Jen Fue ^d   Hodder, Sally ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

CHD incidence; Coronary heart disease; HIV infection

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAID; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0037622824     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308010-00012     Document Type: Article

References (24)

1. Palella F, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
3. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
4. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
5. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Inect Dis. 2000;31:787-797.
6. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
7. Kannel WB. Risk stratification in hypertension: new insights from the Framingham study. Am J Hypertens. 2000;13(1 pt 2):3S-10S.
8. Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. PNAS. 2001;98:10142-10147.
9. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-123.
10. Soodini G, Morgan JP. Can cocaine abuse exacerbate the cardiac toxicity of human immunodeficiency virus? Clin Cardiol. 2001;24:177-181.
11. Howard BV, Rodriguez BL, Bennett PH, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group I: Epidemiology. Circulation 2002;105:e132-e137.
12. Grundy SM, Garber A, Goldberg R, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: Life-style and Medical Management of Risk Factors. Circulation 2002;105:e153-e158.
13. Trespalacios FC, Taylor AJ, Agodoa, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int. 2002;62:1799-1805.
14. Srinivasan B, Allen-Brady K, Cheung AK, et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int. 2002;62:1776-1783.
15. Joint National Committee on Detection. Evaluation and treatment of high blood pressure. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988;148:1023-1038.
16. Rickerts V, Brodt HR, Staszewski S, et al. Incidence of myocardial infarction in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-Cohort Study. Eur J Med Res. 2000;5:329-333.
17. Bozzette SA, Ake C, Carpenter A, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
18. Klein D, Hurley L, Quesenberry CB, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? JAIDS 2002;30:471-477.
19. Tabib A, Leroux C, Mornex JF, et al. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis. 2000;11:41-46.
20. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
21. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100:700-705.
22. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis. 2002;34:98-102.
23. th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003. Boston.
24. Law M, Friis-Moller N, Weber R, et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med. 2003;4:1-10.